Clinical trial
Interventional Treatment of Lung Cancer (LC) With LC Specific Immune Lymphocytes (LC-CTLs)
NCT03353428 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Interventional Treatment of Lung Cancer (LC) With LC Specific Immune Lymphocytes (LC-CTLs)
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- Phase
- Phase 1/2
- Overall status
- Withdrawn
- Start date
- November 15, 2017
- Completion date
- December 31, 2020
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
lung cancer, nsclc